Biomarker for Craving and Acamprosate Treatment Response in Patients with Alcohol Use Disorder: Insights From Multi-Omics

Why It Matters

The biomarker panel enables clinicians to personalize acamprosate therapy, potentially increasing remission rates and reducing costly relapses in the AUD population.

Key Takeaways

• IL17RB variant predicts acamprosate efficacy
• Plasma TNFSF10 levels associate with reduced craving
• Serotonin‑kynurenine pathway linked to treatment response
• ER stress markers correlate with acamprosate outcomes
• Multi‑omics panel supports personalized AUD management

Pulse Analysis

The search for reliable biomarkers in alcohol use disorder has intensified as clinicians seek to move beyond trial‑and‑error prescribing. Recent multi‑omics research bridges this gap by combining genomic, proteomic, and metabolomic data to pinpoint biological signals that forecast how patients will respond to acamprosate, a frontline anti‑craving medication. By leveraging large‑scale genome‑wide association studies, the investigators uncovered variants in the IL17RB gene that consistently predict favorable outcomes, offering a genetic foothold for patient stratification. Complementary proteomic analyses revealed that higher circulating levels of TNFSF10, a cytokine involved in immune modulation, correlate with diminished craving intensity, suggesting an immunometabolic axis influencing treatment success.

Beyond genetics, the study illuminated metabolic pathways that intersect with neuropsychiatric processes underlying addiction. Alterations in serotonin and kynurenine metabolites, driven by TSPAN5‑related mechanisms, were linked to both craving severity and acamprosate responsiveness, underscoring the role of neurotransmitter balance in therapeutic efficacy. Additionally, markers of endoplasmic reticulum stress and IRF3 activation emerged as predictors, hinting that cellular stress responses may modulate drug metabolism or neural plasticity during recovery. These insights expand the mechanistic framework of AUD, positioning metabolic and stress pathways as potential adjunct targets for future interventions.

The practical implications are substantial. A validated biomarker panel could be incorporated into clinical workflows, allowing physicians to identify patients most likely to benefit from acamprosate and to avoid unnecessary exposure for non‑responders. This precision approach promises to improve remission rates, lower healthcare costs associated with relapse, and accelerate the broader adoption of personalized medicine in addiction treatment. As regulatory bodies and payers increasingly demand evidence‑based, outcome‑driven care, such multi‑omics‑derived tools are poised to become integral components of AUD management strategies.